Stock NUVB NUVATION BIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Nuvation Bio Inc.

Equities

NUVB

US67080N1019

Real-time Estimate Cboe BZX
Other stock markets
 03:53:30 2024-06-06 pm EDT 		5-day change 1st Jan Change
2.9 USD +3.57% Intraday chart for Nuvation Bio Inc. -3.85% +90.40%
Jun. 01 Nuvation Bio Inc. Announces Data from Pivotal Phase 2 Trust-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, Publishes in Journal of Clinical Oncology and Reports at 2024 ASCO Annual Meeting CI
May. 14 Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
BU
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
BU
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BU
Nuvation Bio : Acquisition/Asset Disposal - Form 8-K
PU
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
BU
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
BU
Thinking about buying stock in BigBear.ai, Bitfarms, Paysign, Nuvation Bio, or One Group Hospitality?
PR
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
BU
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
BU
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
BU
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
BU
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
BU
Nuvation Bio Announces Departure of Chief Financial Officer
BU
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
BU
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
BU
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
BU
NUVATION BIO INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
NUVATION BIO INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NUVB Stock
  4. News Nuvation Bio Inc.
  5. Press Releases